NBRV Nabriva Therapeutics plc

Price (delayed)

$1.16

Market cap

$410.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.38

Enterprise value

$363.65M

Highlights
NBRV's equity has soared by 176% YoY and by 66% from the previous quarter
Nabriva Therapeutics's EPS has soared by 64% YoY and by 30% from the previous quarter
NBRV's gross profit is up by 40% QoQ but it is down by 30% YoY
Nabriva Therapeutics's revenue has increased by 35% QoQ but it has decreased by 21% YoY
The company's debt rose by 6% YoY

Key stats

What are the main financial stats of NBRV
Market
Shares outstanding
354.2M
Market cap
$410.87M
Enterprise value
$363.65M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.28
Price to sales (P/S)
45.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.74
Earnings
Revenue
$6.77M
EBIT
-$59.1M
EBITDA
-$58.13M
Free cash flow
-$65.01M
Per share
EPS
-$0.38
Free cash flow per share
-$0.25
Book value per share
$0.22
Revenue per share
$0.03
TBVPS
$0.3
Balance sheet
Total assets
$79.41M
Total liabilities
$24.42M
Debt
$7.8M
Equity
$54.99M
Working capital
$60.14M
Liquidity
Debt to equity
0.14
Current ratio
4.29
Quick ratio
3.24
Net debt/EBITDA
0.81
Margins
EBITDA margin
-859%
Gross margin
87.9%
Net margin
-889.7%
Operating margin
-877.6%
Efficiency
Return on assets
-92.7%
Return on equity
-142.7%
Return on invested capital
-545.8%
Return on capital employed
-96.7%
Return on sales
-873.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBRV stock price

How has the Nabriva Therapeutics stock price performed over time
Intraday
5.45%
1 week
4.5%
1 month
-10.08%
1 year
52.63%
YTD
-52.07%
QTD
-14.07%

Financial performance

How have Nabriva Therapeutics's revenue and profit performed over time
Revenue
$6.77M
Gross profit
$5.95M
Operating income
-$59.39M
Net income
-$60.21M
Gross margin
87.9%
Net margin
-889.7%
NBRV's gross profit is up by 40% QoQ but it is down by 30% YoY
The company's net margin rose by 36% QoQ and by 11% YoY
Nabriva Therapeutics's revenue has increased by 35% QoQ but it has decreased by 21% YoY
The operating margin is up by 33% since the previous quarter and by 7% year-on-year

Growth

What is Nabriva Therapeutics's growth rate over time

Valuation

What is Nabriva Therapeutics stock price valuation
P/E
N/A
P/B
5.28
P/S
45.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.74
Nabriva Therapeutics's EPS has soared by 64% YoY and by 30% from the previous quarter
NBRV's equity has soared by 176% YoY and by 66% from the previous quarter
NBRV's P/B is 71% below its 5-year quarterly average of 18.4 and 61% below its last 4 quarters average of 13.7
The P/S is 80% below the 5-year quarterly average of 232.1 and 62% below the last 4 quarters average of 120.5
Nabriva Therapeutics's revenue has increased by 35% QoQ but it has decreased by 21% YoY

Efficiency

How efficient is Nabriva Therapeutics business performance
The return on invested capital has dropped by 67% year-on-year but it rose by 22% since the previous quarter
The ROE is up by 40% year-on-year and by 31% since the previous quarter
Nabriva Therapeutics's ROS has increased by 35% from the previous quarter and by 9% YoY
Nabriva Therapeutics's ROA has increased by 26% from the previous quarter and by 17% YoY

Dividends

What is NBRV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBRV.

Financial health

How did Nabriva Therapeutics financials performed over time
The company's total assets has surged by 94% YoY and by 36% QoQ
The current ratio is up by 39% since the previous quarter and by 34% year-on-year
The company's debt is 86% lower than its equity
NBRV's equity has soared by 176% YoY and by 66% from the previous quarter
The debt to equity has plunged by 62% YoY and by 39% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.